Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation
therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or
olaparib in participants with Extensive-Stage Disease Small Cell Lung Cancer (ES-SCLC) who
have completed a first-line platinum-based chemotherapy regimen and achieved ongoing complete
response (CR), partial response (PR) or stable disease (SD).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute